Pharmacodynamic study of antiangiogenic therapy in patients with renal cell carcinoma.

TPS155 Background: In recent years rationally designed targeted molecules have improved progression free survival in selected tumour types. These agents are primarily cytostatic and it is increasingly obvious that ‘conventional’ pharmacodynamic (PD) end points are no longer adequate in evaluating their activity. The incorporation of novel PD biomarkers in proof of mechanism early phase studies to confirm desired target effect is increasingly frequent, as these may serve as early indicators of drug activity and facilitate early go/no-go decisions in drug development. In this study, imaging biomarkers of tissue perfusion and hypoxia are being used to assess the PD effects of bevacizumab, a humanised anti-VEGF monoclonal antibody. Plasma biomarkers are being used to compare the PD effects of bevacizumab, with those of the multi-targeted tyrosine kinase inhibitor, pazopanib in patients with renal cancer. Methods: This is a single-centre, two-part, exploratory study. Eligibility criteria include patients with ...